|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | RhoA and cytoskeletal disruption mediate reduced osteoblastogenesis and enhanced adipogenesis of human mesenchymal stem cells in modeled microgravity显示文摘 | Meyers V E Zayzafoon M Douglas J T McDonald J M | 2005 | J Bone Miner Res2005，20，10： | 1 |
| 2 | Multicriteria optimization with a multiobjective golden section line search显示文摘 | Douglas A G V Ricardo H C T Rodney R S | 2012 | Mathematical Programming2012，131，12： | 1 |
| 3 | Nanophase Cobalt oxyhydroxide mineral syn- thesized within the protein cage of ferritin显示文摘 | Douglas T Stark V T | 2000 | Inorganic Chemistry2000，39，8： | 1 |
| 4 | Platelet-rich fibrin mem- branes as scaffolds for periosteal tissue engineering显示文摘 | Gassling V Douglas T Warnke P H | 2010 | Clin Oral Implants Res2010，21，5： | 1 |
| 5 | Platelet -rich fibrin membranes as scaffolds for periosteal tissue engineering 显示文摘 | GASSLING V DOUGLAS T WARNKE P H el al | 2010 | Clin Oral Implants Res2010，21，5： | 1 |
| 6 | Platelet-rich fibrin membranes as scaffolds for periosteal tissue engineering显示文摘 | GASSLING V DOUGLAS T WARNKE P H | 2010 | Clin Oral Implants Res2010，21，5： | 1 |
| 7 | Management of Oral Mucositis in Patients with Cancer显示文摘 | Rajesh V L Stephen T S Douglas E | 2008 | Dent Clin North Am2008，52，1： | 1 |
| 8 | Nanophase cobalt oxyhydroxide mineral synthesized within the protein cage of ferritin显示文摘 | DOUGLAS T STARK V T | 2000 | Inorganic Chemistry2000，39，8： | 1 |
| 9 | IN services for converged (Internet) telephony显示文摘 | Douglas J Gurbani V K | 2000 | IEEE Communication Magazine2000，37，6： | 1 |
| 10 | Spatial harmonics of the field in a quadrupole mass filter with circular electrodes 显示文摘 | DOUGLAS D J GLEBOVA T A KONENKOV N V | 1999 | Technical Physics1999，44，10： | 1 |
| 11 | Structural Snapshots of Human HDAC8 ProvideInsights into the Class I His- tone Deacetylases显示文摘 | John RS Robert JS Bradley AK Clifford M Joseph DH Andy JJ Christine L Andrew A Joseph JB Ellen C Jie T Bi CS Erik V Robert W Ellen ML Douglas RD Gyorgy S Marc N Mark WK Ronald VS Duncan EM and Leslie WT | 2004 | Structure2004，12，： | 1 |
| 12 | Chemokine receptor expression by human syncytiotrophoblast显示文摘 | Thirkill T L Sideris V | 2001 | J Reprod Immunol2001，49，： | 1 |
| 13 | Platelet-rich fibrin membranes as scaffolds for periosteal tissue engineering显示文摘 | Gassling V Douglas T Warnke P H | 2010 | Clin Oral Implants Res2010，21，5： | 1 |
| 14 | Platelet‐rich fibrin membranes as scaffolds for periosteal tissue engineering显示文摘 | Gassling V Douglas T Warnke PH | 2010 | Clin Oral Implants Res2010，21，5： | 1 |
| 15 | Pharmacokinetics of Doxycycline in Dogs显示文摘 | Wilson B C Douglas T Kemp V | 1988 | Can J Vet1988，52，： | 1 |
| 16 | 查看详情显示文摘 | Neil G R Bohn C L Benson S V Biallas G Douglas D Dylla H F Evans R Fugitt J Grippo A Gubeli J Hill R Jordan K Li R Merminga L Piot P Preble J Shinn M Siggins T Walker R Yunn B | | 0，，： | 1 |
| 17 | Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results显示文摘AIM To assess the real-world effectiveness and cost of simeprevir(SMV), and/or sofosbuvir(SOF)-based therapy for chronic hepatitis C virus(HCV) infection.METHODS The real-world performance of patients treated with SMV/SOF ± ribavirin(RBV), SOF/RBV, and SOF/RBV with pegylated-interferon(PEG) were analyzed in a consecutive series of 508 patients with chronic HCV infection treated at a single academic medical center. Patients with genotypes 1 through 4 were included. Rates of sustained virological response-the absence of a detectable serum HCV RNA 12 wk after the end of treatment [sustained virological response(SVR) 12]-were calculated on an intention-to-treat basis. Costs were calculated from the payer's perspective using Medicare/Medicaid fees and Redbook Wholesale Acquisition Costs. Patient-related factors associated with SVR12 were identified using multivariable logistic regression.RESULTS SVR 12 rates were as follows: 86%(95%CI: 80%-91%)among 178 patients on SMV/SOF ± RBV; 62%(95%CI: 55%-68%) among 234 patients on SOF/RBV; and 78%(95%CI: 68%-86%) among 96 patients on SOF/PEG/RBV. Mean costs-per-SVR 12 were $174442(standard deviation: ± $18588) for SMV/SOF ± RBV; $223003(± $77946) for SOF/RBV; and $126496(± $31052) for SOF/PEG/RBV. Among patients on SMV/SOF ± RBV, SVR12 was less likely in patients previously treated with a protease inhibitor [odds ratio(OR): 0.20, 95%CI: 0.06-0.56]. Higher bilirubin(OR: 0.47, 95%CI: 0.30-0.69) reduced the likelihood of SVR12 among patients on SOF/RBV, while FIB-4 score ≥ 3.25 reduced the likelihood of SVR 12(OR: 0.18, 95%CI: 0.05-0.59) among those on SOF/PEG/RBV. CONCLUSION SVR 12 rates for SMV and/or SOF-based regimens in a diverse real-world population are comparable to those in clinical trials. Treatment failure accounts for 27% of costs. | Kian Bichoupan Neeta Tandon James F Crismale Joshua Hartman David Del Bello Neal Patel Sweta Chekuri Alyson Harty Michel Ng Keith M Sigel Meena B Bansal Priya Grewal Charissa Y Chang Jennifer Leong Gene Y Im Lawrence U Liu Joseph A Odin Nancy Bach Scott L Friedman Thomas D Schiano Ponni V Perumalswami Douglas T Dieterich Andrea D Branch | 2017 | World Journal of Virology2017，6，4： | 1 |
| 18 | Growth of 'dizzy dendrites' in a random field of foreign particles显示文摘 | GRANASY L PUSZTAI T WARREN J A DOUGLAS J F BORZSONYI T FERREIRO V | 2003 | Nature Materials2003，2，2： | 1 |
| 19 | Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial显示文摘 | Eric Lawitz Jay P Lalezari Tarek Hassanein Kris V Kowdley Fred F Poordad Aasim M Sheikh Nezam H Afdhal David E Bernstein Edwin DeJesus Bradley Freilich David R Nelson Douglas T Dieterich Ira M Jacobson Donald Jensen Gary A Abrams Jama M Darling Maribel Ro | 2013 | The Lancet Infectious Diseases2013，，5： | 1 |
| 20 | Nanophase Cobalt Oxyhydroxide Mineral Synthesized Within the Protein Cage of Ferritin显示文摘 | Douglas T Stark V T | | 0，，08： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员